Study: Pricing for more than 1,200 drugs rose higher than inflation

Drugmakers raised the list prices of more than 1,200 treatments above the 8.5% rate of inflation from July 2021 to July 2022, according to a new report from the Department of Health and Human Services, Axios reports. The HHS report highlights the potential impact of the drug pricing provisions in the Inflation Reduction Act that President Biden signed into law in August, which requires drug companies to pay rebates to Medicare if prices rise beyond the rate of inflation.